Navigating the Corporate Practice of Medicine in Peptide Therapy
A growing prevalence of peptide treatments presents novel complications regarding the corporate practice of medicine. Many states limit non-physician providers from diagnosing, treating patients, and ordering compounds, even within a corporate setting. Thus, understanding the specific regulations